RZLT earnings: next report 2026-09-16, real EPS beat/miss history, analyst consensus Buy, P/E -6.10. Updated 2026-07-23.
Rezolute (RZLT) Research Hub
Rezolute (RZLT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.22 USD (+3.94%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.10, market cap 0.47B. This hub links to the full technical, earnings and options research available for RZLT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.22 USD (+3.94%) |
| 52-week range | 4.02 USD – 5.64 USD |
| Trend regime | Range |
| 14-day RSI | 38.2 (Bearish) |
| Trailing P/E | -6.10 |
| Market cap | 0.47B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-16 |
Available research for RZLT
Covered Call on RZLT: how it works, illustrative setup around the real 4.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RZLT: how it works, illustrative setup around the real 4.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RZLT: how it works, illustrative setup around the real 4.22 USD price, max profit/loss, breakeven and when to use it. Educational.
RZLT technical analysis: range, last 4.22 USD, RSI 38.2, 52w range 4.02 USD–5.64 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RZLT in?
Rezolute (RZLT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RZLT in an uptrend or downtrend?
As of 2026-09-11, RZLT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RZLT's trailing P/E ratio?
RZLT's trailing P/E is -6.10, with a market cap of 0.47B. See the earnings research page for full valuation detail.
When does RZLT next report earnings?
RZLT is next scheduled to report earnings on 2026-09-16, with a consensus EPS estimate of -0.13 USD.